Ordinary Rebalance | European Biotech Index (Net Return) (EUR) | Effective Date 9th October 2023
In the ordinary rebalance, the following composition will be implemented over a period starting on 02.10.2023 cob and ending on 06.10.2023 cob. The new composition will be fully reflected in the index with effective open 09.10.2023:
| ALK-ABELLO A/S |
| ALLIANCE PHARMA PLC |
| ALMIRALL SA |
| AMBU AS CLASS B |
| AVACTA GROUP PLC |
| BAVARIAN NORDIC A/S |
| BICO AB |
| BIONTECH SE |
| BIOTAGE AB |
| CHEMOMETEC A/S |
| DERMAPHARM HOLDING SE |
| EL.EN. S.P.A. |
| EUROFINS SCIENTIFIC SE |
| EVOTEC SE |
| FAES FARMA SA |
| GENUS PLC |
| GERRESHEIMER AG |
| GRIFOLS SA CLASS A |
| GVS SPA |
| HIKMA PHARMACEUTICALS PLC |
| LABORATORIOS FARMACEUTICOS R |
| MORPHOSYS AG |
| ORION OYJ CLASS B |
| OXFORD INSTRUMENTS PLC |
| OXFORD NANOPORE TECHNOLOGIES PLC |
| PHARMA MAR SA |
| PHARMING GROUP NV |
| VALNEVA SE |
| VITROLIFE AB |